Why the study?
Does trimetazidine improve left ventricular performance and reduce lipid peroxidation in patients undergoing elective CABG?
Population
40 patients with good preoperative ejection fraction undergoing elective coronary artery bypass grafting
Comparison
Trimetazidine (TMZ) vs Placebo (PCB)
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
6 hours postoperatively
Authors
Loading...
Trimetazidine should not be used for cardioprotection in elective CABG; confirms no benefit on LV performance or oxidative stress in preserved-EF patients.
Does trimetazidine improve left ventricular performance and reduce lipid peroxidation in patients undergoing elective CABG?
Trimetazidine does not provide significant cardioprotection regarding left ventricular performance or lipid peroxidation during elective CABG in patients with good preoperative ejection fraction.
Vedrinne et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: